# Artificial Intelligence-assisted Insulin System in Type 2 Diabetes in General Wards

Study · id `cardio:ct-nct06319300` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06319300](<https://clinicaltrials.gov/study/NCT06319300>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06319300

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 144 participants.

## Technical summary

Registry record NCT06319300. Randomized; single masking; primary purpose treatment. Start 2024-04-19 (actual); primary completion 2025-09-20 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 144 participants (enrolled count; ClinicalTrials.gov record NCT06319300, source copy `cardio:ctgov-nct06319300-2026-06-23`, retrieved 2026-10-26)
- Started: 2024-04-19 (actual) (ClinicalTrials.gov record NCT06319300, source copy `cardio:ctgov-nct06319300-2026-06-23`, retrieved 2026-10-26)
- Primary completion: 2025-09-20 (actual) (ClinicalTrials.gov record NCT06319300, source copy `cardio:ctgov-nct06319300-2026-06-23`, retrieved 2026-10-26)
- Completion: 2025-09-20 (actual) (ClinicalTrials.gov record NCT06319300, source copy `cardio:ctgov-nct06319300-2026-06-23`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT06319300, source copy `cardio:ctgov-nct06319300-2026-06-23`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06319300-2026-06-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: Artificial Intelligence-assisted Insulin System in Type 2 Diabetes in General Wards
- Condition: Diabetes Type 2
- Intervention (Device): AI-assisted insulin dose adjustment model
- Intervention (Other): doctor's insulin dose adjustment
- Lead sponsor: Shanghai Zhongshan Hospital
- Lead sponsor class: OTHER
- Collaborator: Fudan University
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Shanghai Zhongshan Hospital (`cardio:org-shanghai-zhongshan-hospital`)
- Registry lists this organization as a collaborator: Fudan University (`cardio:org-fudan-university`)

## Provenance

Content hash: e1b4f7d63049864420877f428b6fcfa318b0d40c52344b9d2e8d3f60bed16efe
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
